Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biological Role and Clinical Implications of MYOD1L122R Mutation in Rhabdomyosarcoma

7 Mar 2023

Abstract excerpt

Major progress in recent decades has furthered our clinical and biological understanding of rhabdomyosarcoma (RMS) with improved stratification for treatment based on risk factors. Clinical risk factors alone were used to stratify patients for treatment in the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) RMS 2005 protocol. The current EpSSG overarching study for children and adults with frontline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Sarcoma Diagnosis and Treatment
Share to Tumors and Oncological Cases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36980529
DOI: 10.3390/cancers15061644

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological Role and Clinical Implications of MYOD1L122R Mutation in RhabdomyosarcomaPMID 36980529Read ↗

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.Semantic proximity Read ↗

Clinicopathological Analysis of a European Cohort of MYOD1 Mutant Rhabdomyosarcomas in Children and Young Adults.Semantic proximity Read ↗

MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.Semantic proximity Read ↗

Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-StudiengruppeSemantic proximity Read ↗

Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.Semantic proximity Read ↗

MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.Semantic proximity Read ↗

MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma.Semantic proximity Read ↗

Molecular diagnostics in the management of rhabdomyosarcomaSemantic proximity Read ↗

Molecular profile of head and neck rhabdomyosarcomas: A systematic review and meta-analysis.Semantic proximity Read ↗

The expanding morphological and genetic spectrum of MYOD1 ‐mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non‐mutated casesSemantic proximity Read ↗

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.Semantic proximity Read ↗

Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.